hotspot -WSS

hotspot

author：entertainment 2025-09-30 00:46:29 - browse：7646

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： What don’t we know about an Alzheimer’s drug side effect?

Wikipedia

WSS

Merck to acquire Harpoon Therapeutics for $680 million

Will the market for weight loss drugs really reach $100 billion?

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Medicare Advantage coverage denials need scrutiny, senators say

Allen Institute goes after foundational questions, CEO Costa says

Takeda, Janssen join wearable maker to measure scratching

hotspot

hotspot

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Fauci's latest grilling in Congress: 9 hours, behind closed doors

How one medical school became remarkably diverse

Hospital chaplains balance Covid safety with patients’ spiritual needs

Affirmative action in medical school literally saved lives

Nonprofit, backed by Microsoft, to certify AI tools in health care

Jerome Adams on the need for new antivirals for Covid

Will the market for weight loss drugs really reach $100 billion?

Psychedelics group wrestles with new pharma identity

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

focus

BIO selects John Crowley as new CEO

FDA investigates CAR

Despite FDA concern, risk that CAR

Allen Institute goes after foundational questions, CEO Costa says

Allen Institute goes after foundational questions, CEO Costa says

A preacher's new calling: Diversifying neuroscience research

Wikipedia

explore

entertainment

leisure time